Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2772541 | 0.84 | ALDH1A1 (0.67) | MEN1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL3915052 | 0.82 | HSPB1 (0.47) | MEN1KMT2AMAPTHTTALDH1A1 | |
| SCHEMBL11900645 | 0.79 | CXCR2 (0.58) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3918265 | 0.79 | MAPK1 (0.62) | MEN1KMT2AMAPTTP53CASP3 | |
| SCHEMBL3911920 | 0.78 | TSHR (0.49) | MEN1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL31047229 | 0.78 | TSHR (0.49) | MEN1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL4241741 | 0.77 | ALDH1A1 (0.51) | MAPTALDH1A1CHRNA7 | |
| SCHEMBL2773784 | 0.75 | MEN1 (0.49) | MEN1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL3908318 | 0.74 | CXCR2 (0.47) | MEN1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL2773787 | 0.74 | KCNMA1 (0.45) | MEN1KMT2AMAPTHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9974779-B2 | Piperidine derivatives as human papilloma virus inhibitors | VAXART, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20180021318-A9 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | VAXART, INC. | 2018-01-25 | — | — | US | disclosed |
| US-20170079968-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | AVIRAGEN THERAPEUTICS INC (US) | 2017-03-23 | — | — | US | disclosed |
| US-9452991-B2 | Piperidine derivatives as human papilloma virus inhibitors | AVIRAGEN THERAPEUTICS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| EP-2024350-B1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | ANACONDA PHARMA (FR) | 2013-09-18 | — | — | EP | disclosed |
| CN-101466693-B | Piperidine derivatives as human papilloma virus inhibitors | ANACONDA PHARMA | 2012-12-12 | — | — | CN | disclosed |
| US-20120220633-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | ANACONDA PHARMA | 2012-08-30 | — | — | US | disclosed |
| US-8207373-B2 | Benzoic acid derivatives as human papilloma virus inhibitors | ANACONDA PHARMA (FR) | 2012-06-26 | — | — | US | disclosed |
| US-20090209586-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | ANACONDA PHARMA | 2009-08-20 | — | — | US | disclosed |
| EP-2024350-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | Anaconda Pharma (FR) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007135106-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | ANACONDA PHARMA (FR) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170079968-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | POLI, VHL, EBNA1BP2 | MEN1 4136/4885KMT2A 3026/4885MAPT 3116/4885 |
| US-20180021318-A9 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | POLI, VHL, EBNA1BP2 | MEN1 4136/4885KMT2A 3026/4885MAPT 3116/4885 |
| US-20090209586-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | IDH3A, IDH1, CBR3 | MEN1 4638/4885KMT2A 1518/4885MAPT 4765/4885 |
| US-20120220633-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | IDH3A, CBR3, CBR1 | MEN1 4720/4885KMT2A 1333/4885MAPT 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.